

1           **Long-term clinical and patient reported outcomes of an**  
2                           **enhanced monofocal intraocular lens**

3

4

5   Catharina Latz<sup>1\*</sup>, Annika Licht<sup>1</sup>, Katharina A. Ponto<sup>1,2</sup>, Johannes Menzel-Severing<sup>1,3</sup>,  
6   David P. Piñero<sup>4</sup>, Alireza Mirshahi<sup>1</sup>

7

8   <sup>1</sup>Dardenne Eye Hospital, Bonn, Germany, Germany

9   <sup>2</sup>Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany

10   <sup>3</sup>Department of Ophthalmology, University of Düsseldorf, Düsseldorf, Germany

11   <sup>4</sup>Department of Optics, Pharmacology and Anatomy, University of Alicante, Sant Vicent  
12   del Raspeig, Alicante, Spain

13

14   \* Corresponding author

15   E-mail: [c\\_latz@hotmail.com](mailto:c_latz@hotmail.com)

16

## 17 **Abstract**

18 **Purpose:** To evaluate long-term clinical and patient-reported outcomes (PROMs)  
19 following the implantation of an enhanced monofocal intraocular lens (IOL).

20 **Methods:** This ambispective non-comparative single-centre study involved 41 patients  
21 (ages 48-84) who underwent bilateral cataract surgery with the Tecnis Eyhance IOL  
22 (model ICB00, Johnson & Johnson Vision). Distance and intermediate visual acuities,  
23 refraction, and PROMs were assessed 18 months or more after surgery. Spectacle  
24 independence was evaluated using the PRSIQ questionnaire, with patients self-reporting  
25 on visual quality, difficulties in performing specific tasks and perception of photic  
26 phenomena at distance and intermediate vision.

27 **Results:** At 18 months or later, 100.0%, 73.2%, 100% and 79.5% of patients achieved a  
28 binocular uncorrected distance, uncorrected intermediate, corrected distance, and  
29 distance-corrected intermediate visual acuity of 0.20 logMAR or better, respectively.  
30 Less than 10% of patients reported photic phenomena. Mean visual quality scores were  
31  $1.68 \pm 0.72$  for distance and  $2.05 \pm 0.92$  for intermediate vision (1=very good to 6=very  
32 poor). The dashboard was clearly visible while driving for 95.1% of patients, while 45.0%  
33 could perform screen work without glasses; an additional 40.0% could do so with  
34 enlarged fonts. Complete spectacle independence was reported by 87.8% for distance  
35 vision, and 53.7% for intermediate vision. At least moderately satisfied were 90.2% with  
36 distance vision, 87.8% with intermediate vision, and 51.2% with near vision.

37 **Conclusions:** The enhanced monofocal IOL ICB00 provides good long-term distance  
38 and intermediate visual quality, leading to considerable spectacle independence and  
39 patient satisfaction. Most patients required near vision correction.

## 40 Introduction

41 Presbyopia-correcting IOLs can be categorized by their underlying optical-  
42 physical properties into diffractive and non-diffractive IOLs. While diffractive IOLs split  
43 incoming light through surface discontinuities, non-diffractive IOLs bend light by surface  
44 curvature changes. Another way to categorize IOLs is the range of focus they offer. Full  
45 range of focus (FROF) IOLS cover vision from distance to near, including intermediate  
46 distances. Due to their typically diffractive technology, PROF IOLs may compromise  
47 visual experience through dysphotopsia. Partial range of focus (PROF) IOLs cover a  
48 partial spectrum of vision, typically extending from distance to intermediate, with some  
49 capacity for near vision. They may be diffractive and non-diffractive and create fewer  
50 visual compromises such as dysphotopsias. Most recently, Fernandez et al. offered a  
51 systematic approach to categorize IOL types based on the shape of the defocus curve:  
52 PROF IOLs were divided into narrow, enhanced and extended PROF IOLs<sup>1</sup>.

53 In 2018, the American National Standard Institute (ANSI) provided specific  
54 criteria to define enhanced depth of focus (EDOF) IOLs as IOLs that correct aphakia,  
55 with an extended range of focus above a defined functional visual acuity threshold of 0.2  
56 LogMAR, providing useful distance and intermediate vision with monotonically  
57 decreasing visual acuity from the best distance focal point.<sup>2</sup> With the introduction of a  
58 new technology named Tecnis Eyhance (model ICB00, Johnson & Johnson Vision) in  
59 2019, a new category of intraocular lenses (IOLs) was generated, popularly known as  
60 mono-EDOF, or enhanced monofocal IOLs.<sup>3</sup> According to Fernandez et al<sup>1</sup> this IOL  
61 would be classified as enhanced PROF. This IOL extends the depth of focus similarly to  
62 EDOF IOLs, but does not meet the four effectiveness end-points required to classify it as  
63 true EDOF lenses according to the criteria of the American National Standard Z80.35–  
64 2018 (ANSI).<sup>2</sup> Enhanced monofocal IOLs include some optical modifications to provide

65 an efficacious correction for distance vision while providing an enhanced intermediate  
66 visual function. Various studies have been conducted to characterize the clinical  
67 performance and patient acceptance of the Eyhance IOL and other enhanced monofocal  
68 IOLs.<sup>3-5</sup> Notably, no higher incidence of postoperative photic phenomena was reported  
69 with these IOLs compared to regular monofocal lenses.<sup>6</sup>

70 The Eyhance ICB00 IOL has an aspherical posterior surface and a modified  
71 aspheric anterior surface with a continuous increase in power from the periphery to the  
72 center of the lens while maintaining the distance image quality.<sup>7</sup> The overall lens design  
73 is refractive and leverages the geometry, material, and corneal spherical aberration  
74 correction features, with a higher order aspheric profile included on the anterior optic  
75 surface. As this lens is designed to retain the benefits of a monofocal IOL while adding  
76 intermediate vision, the ICB00 IOL is considered an “enhanced” monofocal IOL designed  
77 to provide improved intermediate vision.<sup>7</sup> A variety of clinical studies have demonstrated  
78 that this IOL provides good distance visual acuity with enhanced intermediate visual  
79 acuity.<sup>8-27</sup> Specifically, enhanced monofocal IOLs provide comparable results in terms of  
80 distance vision compared to conventional monofocal IOLs.<sup>8-27</sup> However, the number of  
81 studies about patient-reported outcomes (PROMs), which reflect the real perception of  
82 the patient regarding the improvement achieved with the implantation of the IOL, is still  
83 limited.<sup>7,11,17,27</sup> Furthermore, long-term real-world data is still scarce. Given that  
84 neuroadaptation and habituation are the basis for patient satisfaction with all refractive  
85 IOLs and that this process takes 6 months and longer, it is of particular interest to analyze  
86 patient-reported outcomes at long term. Also, to satisfactorily manage patient  
87 expectations, it is especially relevant to know the real level of spectacle independence  
88 achieved with this type of enhanced monofocal IOL. The aim of the current study was to  
89 evaluate the long-term clinical and patient-reported outcomes after the implantation of

90 the enhanced monofocal IOL ICB00 with special emphasis on the achieved level of  
91 spectacle independence. In addition, patient satisfaction with this type of IOL in a real-  
92 world setting was analyzed.

## 93 **Methods**

### 94 **Patients**

95 This was an ambispective, non-comparative, single-centre study enrolling a total  
96 of 41 patients who underwent uncomplicated phacoemulsification bilateral cataract  
97 surgery with implantation of the enhanced monofocal IOL ICB00 and had a follow up  
98 visit of 18 months or longer. Recruitment started on October 17, 2023 and ended November  
99 30<sup>th</sup> 2023. The last patient was examined on December 12<sup>th</sup>, 2023. Included were patients  
100 with both eyes having a corneal astigmatism below 0.75D, aged 45 or older, and visually  
101 significant cataract. Exclusion criteria included known systemic diseases with the  
102 potential of altering the outcome of the study, previous ocular surgery including refractive  
103 surgery, irregular astigmatism, zonular alterations that may affect IOL position and  
104 stability, active ocular disease, previous diagnosis of retinal pathologies and severe  
105 glaucoma, as defined by mean deviation deficits of more than 12 dB on visual fields.

106 Before inclusion in the study, each patient was informed in detail about the nature  
107 of the study, and written informed consent was given according to the tenets of the  
108 Declaration of Helsinki. Minors were not included in the study. This study was approved  
109 by the medical ethics committee of the Medical Chamber of North-Rhine, Germany (No:  
110 2023012).

### 111 **Clinical Protocol**

112 All patients underwent a complete preoperative examination, including  
113 measurement of uncorrected distance visual acuity (UDVA) and corrected distance visual  
114 acuity (CDVA), objective refraction by autorefractometry, optical biometry and

115 keratometry (IOLMaster 700, Carl Zeiss Meditec), non-contact tonometry, slit lamp  
116 biomicroscopy, optical coherence tomography of the macula and optic disc (Carl Zeiss  
117 Meditec), and dilated fundus evaluation. In all cases, the Barrett TK formula was used for  
118 IOL power calculation, targeting emmetropia.

119 Postoperatively, patients were evaluated at 1 day and later at the discretion of the referring  
120 physician. Eighteen months after cataract surgery, all patients were contacted by phone  
121 and/or email and scheduled for a long-term follow-up visit. At this visit, a complete visual  
122 evaluation was performed, including the following tests: monocular and binocular  
123 measurement of UDVA and CDVA, manifest refraction, and measurement of uncorrected  
124 intermediate visual acuity (UIVA) and distance-corrected intermediate visual acuity  
125 (DCIVA) (measured at 66 cm). Spectacle independence was evaluated using the Patient-  
126 Reported Spectacle Independence Questionnaire (PRSIQ).<sup>28</sup> We assessed the patient-  
127 reported quality of vision and photic phenomena using a self-developed questionnaire,  
128 where patients quantified the level of distance and intermediate visual quality on a scale  
129 from 1 (excellent) to 6 (extremely poor). Additionally, patients were asked about the  
130 perception of halos, glare, blurring, and starbursts at distance and intermediate vision.

### 131 **Surgery**

132 All surgeries were performed by two experienced surgeons (AM, KT) using a  
133 standard technique of sutureless microincision phacoemulsification. Before surgery,  
134 patients received a peribulbar block (4 mL 0.75% bupivacaine, 2 mL 2% mepivacaine  
135 and 75 IE hyaluronidase (ESTEVE Pharmaceuticals GmbH) and dilating eye drops  
136 (phenylephrine hydrochloride 5%, Ursapharm Arzneimittel GmbH; tropicamide 0.5%,

137 Pharma Stulln GmbH). Patients who were taking warfarin with a high international  
138 normalized ratio received topical anesthesia.

139 A clear corneal incision with a width of 2.4 mm was placed either superior or  
140 temporal as well as two paracenteses (1.0 mm). A manual capsulorhexis was performed  
141 under ophthalmic viscoelastic device (OVD). Care was taken to achieve a capsulorhexis  
142 diameter of approximately 5 mm to ensure complete coverage of the IOL optic with the  
143 anterior capsule. Nuclear disassembly and cortical aspiration were performed using the  
144 Centurion vision system (Alcon). The IOL was delivered either under irrigation or  
145 viscoelastic protection with an injector provided by the manufacturer. At the end of the  
146 procedure, 1 mg cefuroxime and 2mg dexamethasone [4 mg/mL] were administered  
147 intracamerally and subconjunctivally, respectively.

148 Postoperative treatment included a combination eye drop four times a day  
149 containing dexamethasone, neomycin sulfate, and polymyxin-B-sulfate with ointment at  
150 night or, in case of allergies to preservatives, ofloxacin and dexamethasone eyedrops four  
151 times a day. This treatment was tapered over 4 weeks.

## 152 **Statistical analysis**

153 Data analysis was performed using the software SPSS version 22.0 for Windows  
154 (SPSS). Normality of all data distributions was initially evaluated by means of the  
155 Kolmogorov-Smirnov test. A descriptive analysis of all continuous variables was carried  
156 out, calculating the average values with their corresponding standard deviations and the  
157 ranges of maximum and minimum values. For categorical variables, frequencies of  
158 different conditions or aspects were determined. A p-value below 0.05 was considered  
159 statistically significant.

## 160 **Results**

161 **Patient population:** A total of 82 eyes of 41 patients with a mean age of 69.4 years  
 162 (SD: 9.0, median: 70.0, range: 48 to 84 years) was enrolled. The sample comprised 24  
 163 males (58.5%) and 17 females (41.5%).

164 **Refractive outcomes:** Table 1 summarizes the visual and refractive outcomes  
 165 obtained at the last postoperative visit, more than 18 months after surgery: Mean  
 166 postoperative binocular logMAR UDVA and UIVA values were  $0.05 \pm 0.07$  and  $0.18 \pm$   
 167  $0.12$ , respectively.

168

| VA (LogMar)   | Right eye            | Left eye             | Binocular           |
|---------------|----------------------|----------------------|---------------------|
|               | Mean (SD)            | Mean (SD)            | Mean (SD)           |
|               | Median (Range)       | Median (Range)       | Median (Range)      |
| <b>UDVA</b>   | 0.11 (0.10)          | 0.10 (0.09)          | 0.05 (0.07)         |
|               | 0.10 (0.00 to 0.30)  | 0.10 (0.00 to 0.30)  | 0.00 (0.00 to 0.20) |
| <b>CDVA</b>   | 0.05 (0.08)          | 0.04 (0.05)          | 0.02 (0.04)         |
|               | 0.00 (0.00 to 0.30)  | 0.00 (0.00 to 0.20)  | 0.00 (0.00 to 0.10) |
| <b>UIVA</b>   | 0.27 (0.15)          | 0.24 (0.14)          | 0.18 (0.12)         |
|               | 0.30 (0.00 to 0.70)  | 0.20 (0.00 to 0.60)  | 0.20 (0.00 to 0.50) |
| <b>DCIVA</b>  | 0.22 (0.13)          | 0.22 (0.13)          | 0.17 (0.11)         |
|               | 0.20 (0.00 to 0.50)  | 0.20 (0.00 to 0.50)  | 0.20 (0.00 to 0.40) |
| <b>SE (D)</b> | 0.06 (0.47)          | 0.19 (0.53)          | ---                 |
|               | 0.00 (-0.75 to 1.13) | 0.25 (-1.00 to 1.50) |                     |

169

170 **Table 1.- Long-term (18 months or longer) postoperative visual and refractive**  
 171 **outcomes:** CDVA, corrected distance visual acuity; DCIVA, distance-corrected  
 172 intermediate visual acuity; SD, standard deviation; SE, spherical equivalent; UDVA,  
 173 uncorrected distance visual acuity; UIVA, uncorrected intermediate visual acuity.



174

175 Likewise, a mean binocular logMAR DCIVA value of  $0.17 \pm 0.11$  was measured.  
176 100.0%, 73.2%, 100% and 79.5% of patients achieved a binocular UDVA, UIVA, CDVA  
177 and DCIVA of 0.20 logMAR or better, respectively (Figure 1).

178

179 **Figure 1.- Postoperative binocular visual acuity:** uncorrected distance (UDVA),  
180 uncorrected intermediate (UIVA), corrected distance (CDVA) and distance-corrected  
181 intermediate (DCIVA).

182

183 The postoperative spherical equivalent (SE) was within  $\pm 0.50$  D in 80.5% of right eyes  
184 and 82.9% of left eyes. Likewise, postoperative SE was within  $\pm 1.00$  D in 95.1% and  
185 92.7% of right and left eyes, respectively.

186

187 **Patient-reported outcome measurements:** PRSIQ and our own developed  
188 questionnaire were used to assess PROMs: A small percentage of patients reported  
189 postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of  
190 patients reported the perception of halos, blurry vision, and glare at distance vision,  
191 respectively (Figure 2).

192

193 **Figure 2.- Perception of photic phenomena 18 months postoperatively.**

194

195 These percentages decreased to 2.4%, 2.4% and 4.9% for the perception of halos, blurry  
196 vision, and glare at intermediate vision, respectively (Figure 2). Analysis of this subgroup  
197 did not reveal a significantly increased refractive error.

198 The visual quality achieved at distance and intermediate vision was subjectively graded  
199 by the patients on a scale from 1 (very good) to 6 (very poor). This grading scale, adapted  
200 from the German school system, is widely accepted and familiar to patients. Mean  
201 distance and intermediate visual quality satisfaction scores were 1.68 (SD: 0.72; Median:  
202 2.00; Range: 1 to 3) and 2.05 (SD: 0.92; Median: 2.00; Range: 1 to 4), respectively. No  
203 patient provided scores of 4 or worse when asked about satisfaction with distance and  
204 intermediate visual quality. A total of 95.1% of patients reported a clearly visible  
205 dashboard when driving a car. When the dashboard was brightly illuminated, an  
206 additional 97.5 % of patients reported clear visibility. 45% of patients were able to  
207 perform screen work without spectacles, 40% had to enlarge the font and 63.4% of  
208 patients achieved spectacle-free reading when the font size was large enough.  
209 Regarding the level of spectacle independence in the past 7 days, most patients did not  
210 need spectacles for distance vision (87.8%) after surgery, whereas more than half of the  
211 sample evaluated did not need them for intermediate vision (53.7%) (Figure 3A).

212

213 **Figure 3.- Outcomes obtained with the PRISQ questionnaire.**

214

215 In contrast, most patients required glasses for near vision activities (97.6%) (Figure 3A).  
216 Furthermore, a total of 82.5% of patients did not wear glasses at any time for distance  
217 vision during the last 7 days, whereas this percentage decreased to 36.6% for intermediate  
218 vision (Figure 3B).

219 Concerning patient satisfaction, a total of 90.2%, 87.8%, 51.2% and 90.0% of patients  
220 were completely, mostly or moderately satisfied with their unaided distance,  
221 intermediate, near and overall vision, respectively (Figure 3C).

222 No adverse events were recorded during the follow-up, with no cases showing a  
223 development of posterior capsular opacification (PCO) requiring YAG capsulotomy.

224

## 225 **Discussion**

226 To the best of our knowledge this is the first study to demonstrate excellent distance and  
227 good intermediate visual acuities at long term after implantation of the ICB00. No  
228 adverse events were noted. Special emphasis was placed on patients' perception: photic  
229 phenomena were denied for distance or intermediate vision by over 90% of study  
230 participants. Furthermore, 75% of patients were completely or moderately satisfied with  
231 their overall vision. This is consistent with other studies evaluating the same  
232 IOL.<sup>7,10,11,17,25,26</sup> and other models of enhanced monofocal IOLs.<sup>29,30</sup> Goslings et al<sup>11</sup>  
233 reported mean binocular UDVA of  $0.11 \pm 0.11$ , and UIVA of  $0.12 \pm 0.11$  at three months.  
234 These visual results are slightly worse than those in our study, which could be explained  
235 by a different IOL calculation formula, not specified in the publication. Giglio et al.  
236 reported mean postoperative binocular UDVA, UIVA and DCIVA values of  $-0.03 \pm 0.07$ ,  
237  $0.17 \pm 0.12$  and  $0.13 \pm 0.11$ , in 30 eyes using the Barrett Universal II formula.<sup>7</sup> Mencucci  
238 et al. also reported similar mean binocular UDVA, UIVA and DCIVA values ( $0.03 \pm 0.05$   
239 vs.  $0.16 \pm 0.10$  vs.  $0.15 \pm 0.08$ ) in 80 eyes of 40 patients using the Holladay 1 formula for  
240 axial lengths between 22.0 mm and 25.0 mm and Hoffer Q formula for axial lengths equal  
241 to or less than 22.0 mm. Their axial length measurements were obtained using the IOL  
242 master 500 (Carl Zeiss Meditec AG)<sup>26</sup> However, other authors have reported worse  
243 UDVA and better UIVA values in eyes implanted with the ICB00 in which a micro-  
244 monovision approach had been applied or a trend towards a low myopic residual  
245 refractive error was found. ICB00 allows for efficient restoration of distance visual  
246 acuity, with enhanced intermediate visual function.

247 Furthermore, we analyzed how this functional intermediate vision was perceived by  
248 patients. Specifically, we investigated the level of spectacle independence, perceived  
249 difficulties in daily vision-related tasks, and the perception of photic phenomena.  
250 Spectacle independence was evaluated using the PRSIQ questionnaire, a validated  
251 patient-reported measure assessing spectacle independence following cataract surgery.<sup>28</sup>  
252 To this date and to the best of our knowledge, our study is the first to report the level of  
253 spectacle independence achieved with the model ICB00 at 18 months or later. As is  
254 common after cataract surgery with the implantation of any conventional monofocal IOL,  
255 the level of spectacle independence at distance was high: 87.8% of patients were spectacle  
256 or contact lens free at any time of the day. However, for intermediate vision only 53.7%  
257 of patients were spectacle or contact lens free. On the other hand, when examining the  
258 degree of spectacle dependence for intermediate vision, only 21.9% of patients used  
259 spectacle correction all the time or most of the time. Regarding near vision, the level of  
260 spectacle dependence was significant, with 97.6% of patients wearing glasses for such  
261 purposes and 75.6% of them wearing them all the time or most of the time.  
262 Using the PRSIQ tool, Stodulka and Pracharova<sup>31</sup> investigated another IOL with an  
263 optical principle comparable to the IOL type we tested, where a special geometry creates  
264 a power gradient from the centre to the periphery. Spectacle independence with this  
265 EDOF IOL was achieved in over 80% of patients at distance and intermediate vision.  
266 In our study, 90.2% of patients were satisfied with their uncorrected distance and 87.8%  
267 with their uncorrected intermediate vision. This confirms the ability of the enhanced  
268 monofocal IOL model ICB00 to provide satisfactory distance and intermediate visual  
269 outcomes. This is highly relevant since intermediate vision is essential for the use of  
270 computers or equivalent handheld electronic devices such as smartphones and tablets.<sup>32</sup>  
271 Regarding near vision, despite the limitations in terms of visual acuity, approximately

272 half of the sample reported being satisfied with their near visual functionality. This can  
273 be explained by the visual acuity provided, which might allow a variety of near vision  
274 activities without spectacle correction. Indeed, reading activity after surgery was possible  
275 in 14.6% of patients without any additional optical aid, and 63.4% of patients were able  
276 to read without correction if font size was large enough. This finding is supported by  
277 studies by Goslings et al<sup>11</sup> and Giglio et al<sup>7</sup>, who used the validated questionnaire Catquest  
278 9SF to investigate difficulties in performing different vision-related activities after the  
279 implantation of the ICB00 IOL and detected a trend towards improvement in Rasch-  
280 calibrated scores of questions about near vision. Lopes et al<sup>17</sup> evidenced significant  
281 differences between eyes implanted with a conventional monofocal IOL and those  
282 implanted with the model ICB00 in the level of difficulty in reading newspaper print and  
283 reading the prices of goods while shopping, with better outcomes in the group of eyes  
284 implanted with the enhanced monofocal IOL. In our sample, screen work could be  
285 performed postoperatively without correction by 45.0% of patients, with an additional  
286 percentage of 40.0% of patients able to do it without problems if the font was large  
287 enough. Likewise, 95.1% of patients could clearly see the dashboard while driving a car.  
288 These outcomes are consistent with those obtained with the validated questionnaire  
289 Catquest 9SF in other studies evaluating the ICB00, in which the benefit in intermediate  
290 vision with the enhanced monofocal IOL over a conventional monofocal was consistently  
291 perceived by patients.<sup>7,11,17</sup>

292 In accordance with all these PROMs, the level of visual quality graded subjectively by  
293 the patient for distance and intermediate vision was good or very good for all patients,  
294 with no patient reporting poor distance or intermediate visual quality. This was also  
295 consistent with a low percentage of patients perceiving photic phenomena, including  
296 halos, blurry vision, and glare, at distance and intermediate vision (less than 10% in all

297 cases). This aligns with optical simulations that demonstrated fewer halos with the  
298 enhanced monofocal IOL evaluated than with the other two types of extended range of  
299 vision IOLs.<sup>33</sup> Lee and colleagues<sup>34</sup> compared the enhanced monofocal IOL evaluated in  
300 the current study with a diffractive EDOF IOL and found that although spectacle  
301 independence was higher in the diffractive group, this was at the expense of more glare  
302 and halos. Similarly, Corbelli et al<sup>16</sup> found that the enhanced monofocal IOL was not  
303 inferior to a diffractive IOL regarding intermediate visual outcome and spectacle  
304 independence but had the advantage of less perception of halos and glare.

305 Limitations of our study include the lack of a control group with a monofocal IOL as well  
306 as data on corneal spherical aberration of the study patients. Given that neuroadaptation  
307 and habituation take 6 months and longer, this study provides important insights into  
308 patient-perceived outcomes at long term. In view of a growing array of FROF and PROF  
309 IOLs, long term data are very valuable to improve patient satisfaction and patient  
310 counselling.

311 In conclusion, ICB00 provides excellent levels of distance and good intermediate visual  
312 quality, leading to satisfactory levels of spectacle independence and patient satisfaction  
313 at long term. Increased long-term side-effects or increased photic phenomena were not  
314 detected. Near visual outcome, however, was more limited and varied considerably  
315 among subjects.

## 316 **References**

- 317 1.- Fernández J, Ribeiro F, Rocha-de-Lossada C, Rodríguez-Vallejo M. Functional  
318 Classification of Intraocular Lenses Based on Defocus Curves: A Scoping Review and  
319 Cluster Analysis. *J Refract Surg.* 2024;40(2):e108-e116.
- 320 2.- American National Standard for Ophthalmics. ANSI Z80.35-2018: extended depth of  
321 focus intraocular lenses. 2018. Available at: .
- 322 3.- Fernández J, Rocha-de-Lossada C, Zamorano-Martín F, Rodríguez-Calvo-de-Mora  
323 M, Rodríguez-Vallejo M. Positioning of enhanced monofocal intraocular lenses between  
324 conventional monofocal and extended depth of focus lenses: a scoping review. *BMC*  
325 *Ophthalmol.* 2023;23(1):101.
- 326 4.- Redruello-Guerrero P, Rivera-Izquierdo M, Jiménez-Gutiérrez C, Láinez-Ramos-  
327 Bossini AJ, Yela R, López-Marín I. Improvement of intermediate vision with new  
328 monofocal intraocular lenses: A systematic review and meta-analysis. *Eur J Ophthalmol.*  
329 2023;33(3):1308-1319.
- 330 5.- Wan KH, Au ACK, Kua WN, Ng ALK, Cheng GPM, Lam NM, Chow VWS.  
331 Enhanced Monofocal Versus Conventional Monofocal Intraocular Lens in Cataract  
332 Surgery: A Meta-analysis. *J Refract Surg.* 2022;38(8):538-546.
- 333 6.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;  
334 Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced  
335 intermediate function in patients with cataract. *J Cataract Refract Surg.* 2021 Feb  
336 1;47(2):184-191. doi: 10.1097/j.jcrs.0000000000000399. PMID: 32932369.
- 337 7.- Giglio R, Vinciguerra AL, Presotto M, Jonak K, Rejdak R, Toro MD, Nanavaty MA,  
338 Tognetto D. Visual outcomes and patient satisfaction after bilateral implantation of an  
339 enhanced monofocal intraocular lens: a single-masked prospective randomized study. *Int*  
340 *Ophthalmol* 2024;44(1):112.

- 341 8.- Singh G, Sidharthan KS, Reddy JK, Sundaram V, Thulasidas M. Comparison of  
342 visual outcomes in patients implanted with Tecnis Eyhance ICB00 and 1-Piece ZCB00  
343 monofocal intraocular lenses. *Indian J Ophthalmol* 2024;72(2):181-184.
- 344 9.- Negishi K, Masui S, Ayaki M, Torii H, Yotsukura E, Nishi Y. Clinical results and  
345 factors affecting visual function in eyes implanted with an enhanced monofocal  
346 intraocular lens. *Clin Ophthalmol* 2023;17:3965-3973.
- 347 10.- Gigon E, Bouthour W, Panos GD, Pajic B, Massa H. Real world outcomes of the  
348 new Tecnis Eyhance IOL. *Eur J Ophthalmol*. 2023;33(3):1390-1397.
- 349 11.- Goslings O, Veraart H, van de Laar-Muskens J, Piñero DP. Clinical outcomes with  
350 an aspheric monofocal and a new enhanced monofocal intraocular lens with modified  
351 optical profile. *Graefes Arch Clin Exp Ophthalmol*. 2023;261(8):2315-2326.
- 352 12.- Beltraminelli, T., Rizzato, A., Toniolo, K, Galli A, Menghini M. Comparison of  
353 visual performances of enhanced monofocal versus standard monofocal IOLs in a mini-  
354 monovision approach. *BMC Ophthalmol* 2023;23(1):170.
- 355 13.- Choi WK, Han HJ, Son HS, Khoramnia R, Auffarth GU, Choi CY. Clinical outcomes  
356 of bilateral implantation of new generation monofocal IOL enhanced for intermediate  
357 distance and conventional monofocal IOL in a Korean population. *BMC Ophthalmol*  
358 2023;23(1):157.
- 359 14.- Garzón N, Poyales F, Albarrán-Diego C, Rico-Del-Viejo L, Pérez-Sanz L, García-  
360 Montero M. Visual and optical quality of enhanced intermediate monofocal versus  
361 standard monofocal intraocular lens. *Graefes Arch Clin Exp Ophthalmol*.  
362 2022;260(11):3617-3625.
- 363 15.- Steinmüller LN, Greve D, Rua Amaro D, Bertelmann E, von Sonnleithner C.  
364 Analysis of higher-order aberrations in relation to the clinical outcome of an enhanced  
365 monofocal IOL. *Eur J Ophthalmol* 2023;33(6):2096-2105.



- 366 16.- Corbelli E, Iuliano L, Bandello F, Fasce F. Comparative analysis of visual outcome  
367 with 3 intraocular lenses: monofocal, enhanced monofocal, and extended depth of focus.  
368 J Cataract Refract Surg. 2022;48(1):67-74.
- 369 17.- Lopes D, Loureiro T, Carreira R, Rodrigues Barros S, Cardoso JN, Campos P,  
370 Machado I, Campos N. Comparative evaluation of visual outcomes after bilateral  
371 implantation of an advanced or conventional monofocal intraocular lens. Eur J  
372 Ophthalmol. 2022;32(1):229-234.
- 373 18.- Huh J, Eom Y, Yang SK, Choi Y, Kim HM, Song JS. A comparison of clinical  
374 outcomes and optical performance between monofocal and new monofocal with  
375 enhanced intermediate function intraocular lenses: a case-control study. BMC  
376 Ophthalmol 2021;21(1):365.
- 377 19.- Ucar F, Cetinkaya S. The evaluation of a new IOL with extended depth of focus to  
378 increase visual acuity for intermediate distance. SN Compr Clin Med. 2021;3:22852021;  
379 3:2285-2291.
- 380 20.- Kang KH, Song MY, Kim KY, Hwang KY, Kwon YA, Koh K. Visual performance  
381 and optical quality after implantation of a new generation monofocal intraocular lens.  
382 Korean J Ophthalmol. 2021;35(2):112-119.
- 383 21.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;  
384 Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced  
385 intermediate function in patients with cataract. J Cataract Refract Surg. 2021;47(2):184-  
386 191.
- 387 22.- Cinar E, Bolu H, Erbakan G, Yuce B, Aslan F, Fecce M, Emre S. Vision outcomes  
388 with a new monofocal IOL. Int Ophthalmol. 2021;41(2):491-498.

- 389 23.- Unsal U, Sabur H. Comparison of new monofocal innovative and standard  
390 monofocal intraocular lens after phacoemulsification. *Int Ophthalmol.* 2021;41(1):273-  
391 282.
- 392 24.- Yangzes S, Kamble N, Grewal S, Grewal SPS. Comparison of an aspheric monofocal  
393 intraocular lens with the new generation monofocal lens using defocus curve. *Indian J*  
394 *Ophthalmol.* 2020;68(12):3025-3029.
- 395 25.- de Luis Eguileor B, Martínez-Indart L, Martínez Alday N, Sacristán Egüén C,  
396 Cuadros Sánchez C. Differences in intermediate vision: monofocal intraocular lenses vs.  
397 monofocal extended depth of focus intraocular lenses. *Arch Soc Esp Oftalmol (Engl Ed).*  
398 2020;95(11):523-527.
- 399 26.- Mencucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome,  
400 optical quality, and patient satisfaction with a new monofocal IOL, enhanced for  
401 intermediate vision: preliminary results. *J Cataract Refract Surg.* 2020;46(3):378-387.
- 402 27.- Nanavaty MA, Ashena Z, Gallagher S, Borkum S, Frattaroli P, Barbon E. Visual  
403 acuity, wavefront aberrations, and defocus curves with an enhanced monofocal and a  
404 monofocal intraocular lens: a prospective, randomized study. *J Refract Surg*  
405 2022;38(1):10-20.
- 406 28.- Morlock R, Wirth RJ, Tally SR, Garufis C, Heichel CWD. Patient-Reported  
407 Spectacle Independence Questionnaire (PRSIQ): Development and Validation *Am J*  
408 *Ophthalmol* 2017; 178: 101-114.
- 409 29.- Ang RET, Stodulka P, Poyales F. Prospective randomized single-masked study of  
410 bilateral isofocal optic-design or monofocal intraocular lenses. *Clin Ophthalmol*  
411 2023;17:2231-2242.

- 412 30.- Bova A, Vita S. Clinical and Aberrometric Evaluation of a New Monofocal IOL with  
413 Intermediate Vision Improvement. J Ophthalmol. 2022;2022:41196982022;  
414 2022:4119698.
- 415 31.- Stodulka P, Pracharova Z. Evaluation of extended depth-of-focus hydrophobic  
416 intraocular lens with an optic concept based on combination of high-order aberrations.  
417 Ther Adv Ophthalmol 2023 Oct 3:15:25158414231200108.
- 418 32.- Ribeiro F, Cochener B, Kohnen T, Mencucci R, Katz G, Lundstrom M, Casanovas  
419 AS, Hewlett D. Definition and clinical relevance of the concept of functional vision in  
420 cataract surgery ESCRS Position Statement on Intermediate Vision: ESCRS Functional  
421 Vision Working Group. J Cataract Refract Surg. 2020;46 Suppl 1:S1: S1-S3.
- 422 33.- Azor JA, Vega F, Armengol J, Millan MS. Optical assessment and expected visual  
423 quality of four extended range of vision intraocular lenses. J Refract Surg.  
424 2022;38(11):688-697.
- 425 34.- Lee JH, Moon SY, Chung HS, Park SY, Lee H, Kim JY, Tchah H. Clinical outcomes  
426 of a monofocal intraocular lens with enhanced intermediate function compared with an  
427 extended depth-of-focus intraocular lens. J Cataract Refract Surg. 2022;48(1):61-66.




Figure 1




Figure 2






Figure 3